125
Participants
Start Date
October 31, 2012
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
Botulinum toxin type A Dose 1
Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
Botulinum toxin type A Dose 2
Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
Placebo (Normal Saline)
Placebo (Normal Saline) intramuscular injections into specified muscles.
Rochester Clinical Research, Inc, Rochester
Jill Waldo, CCRC, Pittsburgh
NW FL Clinical Research Group, LLC, Gulf Breeze
Pediatric Neurology, PA, Orlando
The Premiere Research Institute at Palm Beach Neurology, West Palm Beach
Nashville Neuroscience Group, Nashville
Josephson Wallack Munshower Neurology, P.C., Indianapolis
Michigan Head Pain & Neurological Institute, Ann Arbor
CORE (Center for Outpatient Research), Springfield
CPFCC Neurology Research Department, Overland Park
Lynn Health Science Institute, Oklahoma City
Texas Association of Pediatric Neurology/Road Runner Research, San Antonio
Advanced Clinical Research, Meridian
Wasatch Clinical Research, Salt Lake City
Phoenix Children's Hospital, Phoenix
Renown Institution for Neurosciences, Reno
The Research Center of Southern California, Oceanside
Fullerton Neurology and Headache Center, Fullerton
San Francisco Clinical Research Center, San Francisco
Stanford Hospital and Clinics, Stanford
Associated Neurologists of Southern CT, P.C., Fairfield
New England Institute for Clinical Research, Stamford
Lead Sponsor
Allergan
INDUSTRY